0001214659-22-010993.txt : 20220908 0001214659-22-010993.hdr.sgml : 20220908 20220908163027 ACCESSION NUMBER: 0001214659-22-010993 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220906 FILED AS OF DATE: 20220908 DATE AS OF CHANGE: 20220908 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Truitt Kenneth CENTRAL INDEX KEY: 0001946056 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38599 FILM NUMBER: 221234162 MAIL ADDRESS: STREET 1: C/O AQUESTIVE THERAPEUTICS, INC. STREET 2: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc. CENTRAL INDEX KEY: 0001398733 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208623253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-941-1900 MAIL ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: MonoSol Rx, Inc. DATE OF NAME CHANGE: 20070507 4 1 marketforms-57083.xml PRIMARY DOCUMENT X0306 4 2022-09-06 0001398733 Aquestive Therapeutics, Inc. AQST 0001946056 Truitt Kenneth C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE WARREN NJ 07059 false true false false Chief Medical Officer Non-Qualified Stock Option (right to buy) 1.25 2022-09-06 4 A false 100000 0 A 2032-09-06 Common Stock 100000 100000 D Granted as an inducement equity award under the Aquestive Therapeutics, Inc. 2022 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5636(c)(4). The options will vest annually 25% on the first and second anniversaries of the Grant Date and 50% on the third anniversary of the Grant Date, subject to Dr. Truitt's continued employment through the applicable vesting date. /s/ Lori Braender, as Attorney-In-Fact 2022-09-08 EX-24 2 poa.htm POA DOCUMENT

      POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints
each of Lori J.
Braender, A. Ernest Toth, Jr., Valerie Borchevsky and Ellen S. Knarr, signing
singly, the
undersigned's true and lawful attorney-in-fact to: (i) execute for and on behalf
of the undersigned,
in the undersigned's capacity as a director of Aquestive Therapeutics, Inc. (the
"Company"), a Form
ID, including updates thereto, and Forms 3, 4, and 5 in accordance with Section
l6(a) of the
Securities Exchange Act of 1934 and the rules thereunder; (ii) do and perform
any and all acts for
and on behalf of the undersigned which may be necessary or desirable to complete
and execute any
such Form ID, including updates thereto, or Form 3, 4, or 5 and timely file such
form with the
United States Securities and Exchange Commission and any stock exchange or
similar authority; and
(iii) take any other action of any type whatsoever in connection with the
foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to, in the best interest of,
or legally
required by, the undersigned, it being understood that the documents executed by
such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
shall be in such
form and shall contain such terms and conditions as such attorney-in-fact may
approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and
perform any and every act and thing whatsoever requisite, necessary, or proper
to be done in the
exercise of any of the rights and powers herein granted, as fully to all intents
and purposes as
the undersigned might or could do if personally present, with full power of
substitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact's
substitute or
substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of
the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer
required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of
and transactions
in securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing
delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this Power of Attorney to be executed
day 6th day of September 2022


Kenneth E. Truitt, MD